- 600 mg dose of IkT-001Pro selected as the bioequivalent dose relative to standard of care 400 mg imatinib mesylate - - On-track to complete pivotal clinical phase of the 501 study by the end of 2Q22 ...
BOSTON and ATLANTA, June 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results